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OBJECTIVE—To assess the effect of diacerein on insulin secretion and metabolic control in
drug-naïve patients with type 2 diabetes.
RESEARCHDESIGNANDMETHODS—Arandomized,double-blind,placebo-controlled
clinicaltrialwas carried out in 40 drug-naïve adult patients with type 2 diabetes. A metabolic proﬁle
includinginterleukin(IL)-1b,tumornecrosisfactor-a,IL-6,andfastinginsulinlevelswascarriedout
beforetheinterventionand2monthsafterward.Ahyperglycemic-hyperinsulinemicclamptechnique
was performed to assess the phases of insulin secretion and insulin sensitivity. After randomization,
20patientsreceiveddiacerein(50mgoncedaily)fortheﬁrst15daysandtwicedailyfor45additional
days. The remaining patients received placebo. Intra- and intergroup differences were calculated by
Wilcoxon signed rank and Mann-Whitney U tests.
RESULTS—Thereweresigniﬁcantincreasesinﬁrst(102663vs.130675pmol/L;P,0.01),
late(2196111vs.2806135pmol/L;P,0.01),andtotalinsulin(178691vs.216699pmol/L;
P,0.01)secretionswithoutchangesininsulinsensitivityafterdiacereinadministration.Therewere
signiﬁcantdecreasesinfastingglucose(7.961.4vs.6.861.0mmol/L;P,0.01)andinA1Clevels
(8.3 6 1.0 vs. 7.0 6 0.8%; P , 0.001) after diacerein administration. There were no signiﬁcant
changes after placebo administration in the above-mentioned evaluations.
CONCLUSIONS—Insulin secretion increased and metabolic control improved after diacerein
administration in drug-naïve patients with type 2 diabetes.
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t has been suggested that several epi-
genetic factors are involved in the path-
ogenesis of type 2 diabetes; however, its
development is at least partially a direct
consequence of obesity (1,2). Obesity is
associated with a low-grade chronic in-
ﬂammatory state, which to a large extent
emanatesfromadiposetissue.Withitsse-
cretion of bioactive molecules, this may
have an effect on insulin sensitivity in
the liver and peripheral tissues as well as
oninsulinsecretion,withanegativeimpact
on the cardiovascular system (3,4). Some
cytokines, in particular, tumor necrosis
factor-a (TNF-a) and interleukin (IL)-1b,
are involved in apoptosis of b-cells, de-
creasing insulin secretion with the conse-
quent hyperglycemia (4,5).
Diacerein is a medication used fre-
quently in the treatment of some articular
diseases as a result of its effect on the
inﬂammatory process (6,7). Diacerein
decreases cytokine concentrations, in
particular, TNF-a and IL-1b,w i t ha nu n -
knownmechanism ofaction(7,8).There-
fore, if diacerein is prescribed for obese
patients with type 2 diabetes, it may de-
crease cytokines, increase insulin secretion
and probably insulin action, and thereby
improve glucose control.
Theaimofthisstudywastoassessthe
effectofdiacereinoninsulinsecretionand
metabolic control in drug-naïve patients
with type 2 diabetes.
RESEARCH DESIGN AND
METHODS—A randomized, double-
blind, placebo-controlled clinical trial was
carried out in 40 drug-naïve adults (40–
60 years of age) with type 2 diabetes with
,6 months since diagnosis. They were
overweight or obese (BMI 25.0–34.9
kg/m
2), hadfastingglucoselevelsbetween
7.0 and 11.1 mmol/L, and had A1C levels
between7and9%.Thestudyprotocolwas
reviewed and approved by the hospital-
based ethics committee, and written in-
formed consent was obtained from all
volunteers. Subjects were selected from
the same residential area and socioeco-
nomic status. No participant was exces-
sively sedentary or participated in heavy
physical activity. All individuals were
nonsmokers. Their body weight was sta-
ble for at least 3 months before the study.
Blood pressure was ,130/80 mmHg.
None of the subjects had a personal his-
tory of hepatic, renal, or coronary artery
disease. Subjects denied use of any med-
ications known to affect metabolism dur-
ing the previous 6 months.
All patients received general recom-
mendations about their medical nutri-
tional therapy and were instructed to
not modify their usual forms of exercise.
Before testing, an isocaloric diet of at least
250 g of carbohydrates per day was given
for 3 days. Women were in the ﬁrst phase
of their menstrual cycle (3–8d a y s ) .
Tests, before and 2 months after the
pharmacological intervention, were per-
formed at 8:00 A.M. after a 10- to 12-h
overnight fast. Weight and height were
recorded with the subjects wearing light
clothing and without shoes. Height was
measured and rounded off to the nearest
centimeter with the subjects standing.
BMIwascalculatedasweight(kg)divided
by height (m
2). Waist circumference was
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ORIGINAL ARTICLEtaken at the midline between the highest
pointoftheiliaccrestandthelowestribin
the midaxillary line. Blood pressure was
evaluatedbytheinvestigatoraftera5-min
resting period with the individual sitting
in a chair and determined using a stan-
dard mercury sphygmomanometer. Sys-
tolic and diastolic blood pressures were
based on Korotkoff phases I and V, re-
spectively. Venous blood was obtained
with the subject supine in a quiet room.
Blood was allowed to clot for 30 min at
room temperature and then centrifuged.
The resulting serum was placed into two
aliquots. The ﬁrst one was immediately
used for the measurement of serum glu-
c o s e ,A 1 C ,t o t a lc h o l e s t e r o l( T C ) ,H D L
cholesterol (HDL-C), and triglycerides
(TGs). The second aliquot was frozen at
220°C for measurement of IL-1b,T N F - a,
IL-6, and fasting insulin levels within
the following 30 days. A hyperglycemic-
hyperinsulinemic clamp technique was
performed to assess the phases of insulin
secretion and insulin sensitivity (9,10).
Brieﬂy, two venous accesses were in-
stalled: the ﬁrst one retrograde over
some of the veins of the hand through a
19-gauge butterﬂy catheter for taking
samples during the test. The hand was
wrapped in a thermal pillow to achieve a
local temperature .40°C to arterialize the
blood. The second access was installed on
the contralateral arm with a 19-gauge
catheter. A 20% dextrose infusion was
initiated:aprimingdosefor14minequiv-
alent to 240 mg/kg body wt followed by a
maintenance dose based on body weight,
basal glucose, and the glucose required
throughout the test (6.9 mmol/L above
basal value). At 2, 4, 6, 8, and 10 min,
5 mL of blood was taken and after that, at
every 10 min until 120 min for insulin
determination. At 5-min intervals, we
took an additional 1.5-mL blood sample
for glucose determination to calculate the
estimate of glucose metabolism and to be
abletoadjusttherateofdextroseinfusion.
At the end of the test (120 min), dextrose
infusion was maintained for 30 min as a
precaution to avoid hypoglycemia. With
the above-mentioned results and using a
calculator program, ﬁrst (0–10 min) and
late (10–120 min) phases of insulin secre-
tion as well as total insulin concentration
(0–120 min) were calculated, and total
glucose metabolism was used to evaluate
insulin sensitivity.
The allocation was concealed and
done by simple randomization with a
closed envelope that contained a letter A
or B. After randomization, 20 patients
receiveddiacerein(RepresentacioneseIn-
vestigaciones Médicas, SA de CV, Mexico
City, Mexico) (50 mg once daily during
the ﬁrst 15 days and twice daily for 45
additional days). The other 20 subjects
received placebo in the same pharmaco-
logical presentation for 60 days.
Serum glucose was determined by
the glucose-oxidase technique (Analox
Instruments Ltd., London, U.K.) with
an intra- and interassay coefﬁcient of
variation,1%.A1Clevelsweremeasured
usingion-exchangehigh-performanceliq-
uid chromatography technique (Bio-Rad
Laboratories, Hercules, CA) with an intra-
and interassay coefﬁcient of variation of
0.4 and 1.6%, respectively. Serum lipid
levels (TC, HDL-C, and TG) were mea-
sured enzymatically. In particular, HDL-C
wasassessedafterselectiveprecipitationof
non-HDL-C fractions. Determinations
were performed with commercially avail-
ableequipment(Ortho-ClinicalDiagnos-
tics, Rochester, NY) with an intra- and
interassay coefﬁcient of variation ,3%.
IfTGlevelswere,4.4mmol/L,LDLcho-
lesterol (LDL-C) was estimated by the
Friedewald formula (LDL-C = TC 2
HDL-C 2 TG/5) and VLDL cholesterol
(VLDL-C) by TG/5. ELISA was used to
measure IL-1b,T N F - a, and IL-6 concen-
trations (BenderMedSystems,Burlingame,
CA) with an intra- and interassay coefﬁ-
cient of variation for all (,3.5 and ,6.7%,
respectively). Insulin concentrations were
measured with microparticle enzymatic
immunoassay method (Abbott Diagnos-
tics Division, Japan Co. Ltd., Wiesbaden,
Germany) with an intra- and interassay
coefﬁcient of variation of 3.3 and 3.8%,
respectively.
Statistical analyses
Sample size was calculated by means of a
formula for clinical trials (11) with a sta-
tistical conﬁdence of 95%, statistical
power of 80%, SD for A1C of 1.5%, and
an expected difference of at least 1.5% of
A1C between groups, obtaining a total of
20 patients for each group that included
20% of expected loss. With insulin secre-
tion, the calculation of sample size was
smaller. Values were converted to Sys-
tème International units and presented
as mean 6 SD. Primary end points were
considered ﬁrst, late, and total insulin se-
cretionphasesaftertheintervention,aswell
asfastingglucoseandA1Clevels.Intra-and
intergroup differences were calculated by
Wilcoxon signed rank and Mann-Whitney
U tests, respectively; P # 0.05 was consid-
ered signiﬁcant.
RESULTS—All patients who were eli-
gible after enrollment completed the 60
days of the pharmacological intervention,
including 12 women and 8 men in the
placebo group and 9 women and 11 men
in the diacerein group (P = 0.342). There
was no signiﬁcant difference in age be-
tween groups (47.8 6 5.2 vs. 47.5 6 5.3
years, placebo and diacerein, respectively;
P = 0.820). BMI at baseline was similar
between groups (30.8 6 2.4 vs. 30.6 6
2.6 kg/m2, placebo and diacerein, respec-
tively;P=0.968).Therewasnosigniﬁcant
difference at baseline in waist circumfer-
ence between groups in women (97 6 9
vs. 101 6 7 cm, placebo and diacerein,
respectively; P = 0.850) and in men
(112 6 12 vs. 106 6 9 cm, placebo and
diacerein, respectively; P = 0.310). There
were no signiﬁcant differences at baseline
in systolic (120 6 7 vs. 117 6 10 mmHg,
placebo and diacerein, respectively; P =
0.209) and diastolic (78 6 6 vs. 77 6 7
mmHg, placebo and diacerein, respec-
tively; P = 0.892) blood pressures between
groups. There were no signiﬁcant changes
after pharmacological intervention in the
above-mentioned evaluations. No patient
had TG levels .4.4 mmol/L.
Table 1 shows laboratory measure-
ments at baseline and after pharmacologi-
cal intervention in both groups. Signiﬁcant
decreases in fasting glucose, A1C, TNF-a,
and IL-1b concentrations with a tendency
(P = 0.064) in VLDL-C, as well as signiﬁ-
cantincreases inﬁrst,late,andtotalinsulin
secretions after diacerein administration,
were observed.
T h e r ew e r es i g n i ﬁcant changes from
baseline to the end of the study in fasting
glucose (0.6 vs. 21.1 mmol/L, placebo
and diacerein, respectively; P =0 . 0 0 5 ) ,
A1C(0.1vs.21.3%,placeboanddiacerein,
respectively; P , 0.001), TGs (0.1 vs. 20.3
mmol/L, placebo and diacerein, respec-
tively; P = 0.015), VLDL-C (0.0 vs. 20.1
mmol/L, placebo and diacerein, respec-
tively; P = 0.007), TNF-a (20.3 vs.
24.5 pg/mL, placebo and diacerein,
respectively; P , 0.001), and IL-1b
(20.8 vs. 27.5 pg/mL, placebo and
diacerein, respectively; P = 0.003), as
well as signiﬁcant increases in ﬁrst (6 vs.
31 pmol/L, placebo and diacerein, respec-
tively; P , 0.001), late (29 vs. 60 pmol/L,
placebo and diacerein, respectively; P =
0.001), and total (24v s .3 7p m o l / L ,p l a -
ceboanddiacerein,respectively;P=0.008)
insulin secretions.
Gastrointestinal symptoms (9 vs. 13
patients, placebo and diacerein groups,
respectively; P = 0.204) and headache
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IL-1b and TNF-a inhibition on insulin secretion(6 vs. 5 patients, placebo and diacerein
groups, respectively; P = 0.723) were the
most common adverse events after the
pharmacological intervention. Patients
reported no infection during the study
period.
CONCLUSIONS—Alow-gradechronic
inﬂammatorystateispresentinobesityand
diabetes(3).Thisfactmaybearesultofthe
participation of cytokines in defects of in-
sulin secretion and insulin sensitivity ob-
served in those patients (4,5).
As expected, IL-1b and TNF-a levels
decreased after diacerein administration,
resulting in increases in ﬁrst, late, and to-
tal insulin secretions with the consequent
improvement of glycemic control in this
group of patients.
Both cytokines IL-1b and TNF-a are
involved in b-cell apoptosis and in failure
of insulin secretion (4,5). In accordance
with most, but not all, publications in the
medical literature due to differences in
study characteristics, the decrease of cyto-
kineswithseveralpharmacologicalinterven-
tions such as anakinra (12,13), etanercept
(14,15), nonsteroidal anti-inﬂammatory
drugs (16,17), or thiazolidinediones (18,19)
is related to improvement in b-cell function
and insulin secretion.
With our study design, insulin sensi-
tivity was not improved and IL-6 concen-
trations were not decreased with diacerein
administration;however,wecannotexclude
thefactthatalongerinterventiontimecould
modify them. A transient dose-dependent
effect of diacerein on local IL-6 production
has been found (7). Postprandial glucose
was not measured, and this measurement
is, in general, considered a component of
glycemic control; therefore, it may repre-
sentanotherlimitationoftheinvestigation.
Minimal reductions of TG and VLDL-
C levels observed in our patients may be
due to changes in glucose control.
Symptomatic hypoglycemia was not
reportedbyanyofourstudypatients,and
none of the subjects interrupted treatment
as a result of any adverse event. Concern
abouttheinhibitionofinnateimmunityand
the increase of infections appears not to be
justiﬁed because no signiﬁcant increase in
the incidence of infectious diseases with
diacerein has been reported (20). In our
study, this adverse event was not observed,
despite the fact that the study was not de-
signed for such purpose.
Our results suggest that diacerein
administration may have a potential use-
fulness in the treatment of type 2 diabetes
as a possible result of inhibition of IL-1b
andTNF-a.Further studiesareneeded to
test long-term administration, as well as
to explore its use in combination with
other pharmacological options and in pa-
tients with other characteristics.
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